Evaluation of the growth inhibitory effect of erlotinib by the SDI method revealed that cancer cell viability was reduced concentration-dependently in the EGFR mutation-positive cases but hardly in the EGFR-negative cases even at high concentration of up to 20 mM (data not shown). Here, EGFR is linked to cancer.